Epi-on or epi-off? Accelerated or not? A review from Nikki Hafezi and Farhad Hafezi on the current state of the art for CXL treatment of progressive keratoconus
Keratoconus treatment by cross-linking in children and adolescents, at the ELZA Institute (article in German)
L4S21 aims to reduce severe visual impairment among children and adolescents with Down Syndrome
How to enterprise ophthalmology: 3 parties, 3 countries, 3 approaches, with the ELZA Institute
We are very proud to announce that our head of Strategy and BD&L, Nikki Hafezi, MASIP ETHZ, has been voted onto the “Top 40 under 40” list 2015 by her peers.
Ophthalmica.gr holds a press conference on the opening of the LfS21 Reference Center in Thessaloniki.
Nikki Hafezi gives a guide to turning bright ideas into commercial realities
The concept of using photoactivated chromophores for corneal cross-linking (PACK-CXL) as a weapon against infectious keratitis is compelling
Infectious keratitis is a leading cause of global blindness, with an estimated 5 million new cases occurring every year in developing countries
EMAGine SA, a spin-off company from the University of Geneva and co-founded by Nikki and Farhad Hafezi, is elected amongst the best start-ups in Switzerland in 2014
